Drug Profile
RPE65 gene therapy
Alternative Names: REP 65 gene therapyLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Blindness
Most Recent Events
- 07 May 2001 Preclinical development for Leber congenital amaurosis in USA (Intraocular)